Chad Wessel, BIO’s Director of Industry Research, will provide an overview of recent investment and deal trends for emerging therapeutic companies, as well as an update on the R&D pipeline and recent FDA approvals. The BIO Industry Analysis team publishes quarterly interactive data on licensing, M&A, venture capital, IPOs, follow-on public offerings, and FDA approvals at www.bio.org/iareports.